Miraca Holdings
VC Fund
Tokyo, Japan
Miraca Holdings is a VC fund in Tokyo focused on Medical and Biotechnology. Miraca Holdings Inc. is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and healthcare related business
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Miraca Holdings invests in
Stages Miraca Holdings invests in
Countries Miraca Holdings invests in
Investment Focus
Industry
- Medical 4 (57%)
- Biotechnology 3 (43%)
- Consulting 2 (29%)
- Health Care 2 (29%)
- Medical Device 2 (29%)
Stage
- Funding Round 3 (43%)
- Venture - Series Unknown 2 (29%)
- Series A 1 (14%)
- Series C 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Catalyna is a Japan-based company that provides its users with system development and handing solutions. It was founded in 2015 and is headquartered in Tokyo, Japan. | Venture - Series Unknown / Jun 25, 2020 | |
|
|
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumorcells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan. | $104.9M / Apr 04, 2020 | |
|
|
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumorcells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan. | $6.8M / Series C / Mar 02, 2020 | |
|
|
AGREE is an application developer and operator for medical consultation. Its product is the medical consultation application, LEBER. It allows its users to consult with a doctor on their smartphone 24/7. It was founded in 2017 and is headquartered in Tsukuba, Ibaraki Prefecture, Japan. | $3.9M / Venture - Series Unknown / Feb 05, 2020 | |
|
|
SmartScan is a Japanese company that manufactures preventive medicines. SmartScan's mission is to create and provide an image screening environment that is easy for anyone to visit. | $7.3M / Series A / Nov 28, 2019 | |
|
|
JUNTEN BIO is a company is to develop new technologies in the field of regenerative medicine. | $1.8M / Dec 17, 2018 | |
|
|
HIROTSU BIO SCIENCE is a biotechnology company. | $198.4M / Aug 06, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Miraca Holdings invest in?
Miraca Holdings invests primarily in Medical, Biotechnology and Consulting startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Miraca Holdings last invest?
The most recent investment recorded for Miraca Holdings closed in Jun 2020. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!